Jeffrey Tyner, Ph.D.
- click here
- 503 346-0603
"Next-generation medicine: Combining BCR-ABL and hedgehog-targeted therapies,"
"HitWalker: Variant prioritization for personalized functional cancer genomics,"
"A molecular case report: Functional assay of tyrosine kinase inhibitors in cells from a patient's primary renal cell carcinoma,"
"The selective syk inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemias,"
"Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening,"